Evidence map›Paper›PMID 35094871›Full record

ArticleVaccine2022

An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.

Fei Liu, Canbin Feng, Shiqi Xu, Qiang Wu, Jian Tang, Yan Chen, Ruisheng Xu, Fuliang Chen, Ni Gao, Zhengzheng Xu and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Fei LiuAnhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Molecular Diagnosis Center, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital, Bengbu Medical College, No. 287 Changhuai Road, Bengbu, Anhui, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: liufei_2012mdf@163.com.
Canbin FengLaboratory of Genome Editing and Brain Diseases, Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Science, Shanghai 200031, China.
Shiqi XuCAS Key Laboratory of Molecular Virology & Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Qiang WuLaboratory of Genome Editing and Brain Diseases, Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Science, Shanghai 200031, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
Jian TangState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, China.
Yan ChenLaboratory of Genome Editing and Brain Diseases, Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Science, Shanghai 200031, China.
Ruisheng XuLaboratory of Genome Editing and Brain Diseases, Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Science, Shanghai 200031, China.
Fuliang ChenAnhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Molecular Diagnosis Center, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital, Bengbu Medical College, No. 287 Changhuai Road, Bengbu, Anhui, China.
Ni GaoLaboratory of Genome Editing and Brain Diseases, Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Science, Shanghai 200031, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
Zhengzheng XuLaboratory of Genome Editing and Brain Diseases, Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Science, Shanghai 200031, China.
Shihui GuDepartment of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Yang LanShanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Haibo ZhouLaboratory of Genome Editing and Brain Diseases, Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Science, Shanghai 200031, China.
Xinde HuLaboratory of Genome Editing and Brain Diseases, Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Science, Shanghai 200031, China. Electronic address: huxinde@ion.ac.cn.
Xiaojing WangAnhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Molecular Diagnosis Center, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital, Bengbu Medical College, No. 287 Changhuai Road, Bengbu, Anhui, China. Electronic address: wangxiaojing8888@163.com.
Center for Excellence in Brain Science and Intelligence Technology · CNFirst Affiliated Hospital of Bengbu Medical College · CNFudan University · CNInstitut Pasteur of Shanghai · CNUniversity of Chinese Academy of Sciences · CNXiamen University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently needed countermeasure against this ongoing pandemic. Guided by this strong promise of using AAVs, we here designed, optimized, and developed an AAV-based vaccines (including AAV-RBD(max), AAV-RBD(wt), AAV-2xRBD, and AAV-3xRBD) that elicit strong immune responses against the RBD domain of the SARS-CoV-2 S protein. These immunogenic responses have proven long-lived, with near peak levels for at least six months in mice. Notably, the sera immunized with AAV-3xRBD vaccine contains powerful neutralizing antibodies against the SARS-CoV-2 pseudovirus. Further evidence proven that potent specific antibodies could also be elicited in canines after vaccination with AAV-3xRBD vaccine.

Indexed as

COVID-19Viral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesDogsHumansMiceMice, Inbred BALB CSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral VaccinesAAVNeutralizing antibodySARS-CoV-2Vaccine

Identifiers

PMID35094871
PMCPMC8769940
OpenAlexW4206063649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.